Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | CA12 | O43570 | 5/20 | 0.48 |
| ▸ | CA1 | P00915 | 5/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | TYMP | P19971 | 3/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CCR10 | P46092 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12396375 | 0.91 | KMT2A (0.78) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL16473558 | 0.86 | KMT2A (0.68) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL8855553 | 0.85 | KMT2A (0.67) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL8897223 | 0.85 | KMT2A (0.67) | KMT2ACA12CA1CA2CA9 | |
| [18F]Fluoromisonidazole SCHEMBL18401354 | 0.85 | KMT2A (0.67) | KMT2ACA12CA1CA2CA9 | |
| [18F]Fluoromisonidazole SCHEMBL13020421 | 0.85 | KMT2A (0.67) | KMT2ACA12CA1CA2CA9 | |
| Fluoromisonidazole SCHEMBL368122 | 0.85 | KMT2A (0.67) | KMT2ACA12CA1CA2CA9 | |
| [18F]Fluoromisonidazole SCHEMBL17022268 | 0.85 | KMT2A (0.67) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL2358150 | 0.85 | KMT2A (0.71) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL1615079 | 0.85 | KMT2A (0.67) | KMT2ACA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518371-B2 | Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof | NATURAL PHARMACIA INTERNATIONAL, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518371-B2 | Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof | NATURAL PHARMACIA INTERNATIONAL, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518371-B2 | Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof | NATURAL PHARMACIA INTERNATIONAL, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110085975-A1 | HYPOXIA-SELECTIVE, WEAKLY BASIC 2-NITROIMIDAZOLE DELIVERY AGENTS AND METHODS OF USE THEREOF | NATURAL PHARMACIA INTERNATIONAL, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110085975-A1 | HYPOXIA-SELECTIVE, WEAKLY BASIC 2-NITROIMIDAZOLE DELIVERY AGENTS AND METHODS OF USE THEREOF | NATURAL PHARMACIA INTERNATIONAL, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110085975-A1 | HYPOXIA-SELECTIVE, WEAKLY BASIC 2-NITROIMIDAZOLE DELIVERY AGENTS AND METHODS OF USE THEREOF | NATURAL PHARMACIA INTERNATIONAL, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-7842278-B2 | Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof | NATURAL PHARMACIA INTERNATIONAL, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842278-B2 | Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof | NATURAL PHARMACIA INTERNATIONAL, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842278-B2 | Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof | NATURAL PHARMACIA INTERNATIONAL, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| CN-101668547-A | Select the alkalescence 2-nitroimidazole delivery agents and the application process thereof of oxygen-starved tissue | NATURAL PHARMACIA INTERNATIONA | 2010-03-10 | — | — | CN | disclosed |
| US-20080102026-A1 | Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof | NATURAL PHARMACIA INTERNATIONAL, INC. | 2008-05-01 | — | — | US | disclosed |
| US-20080102026-A1 | Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof | NATURAL PHARMACIA INTERNATIONAL, INC. | 2008-05-01 | — | — | US | disclosed |
| US-20080102026-A1 | Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof | NATURAL PHARMACIA INTERNATIONAL, INC. | 2008-05-01 | — | — | US | disclosed |
| EP-1844022-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2007-10-17 | — | — | EP | disclosed |
| EP-1404376-A4 | RADIOPHARMACEUTICAL FORMULATIONS | BRACCO IMAGING SPA (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006071017-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
| US-20050187198-A1 | Methods of preparing substituted tetracyclines with transition metal-based chemistries | TRUSTEES OF TUFTS COLLEGE (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050074402-A1 | Radiopharmaceutical formulations | BRACCO IMAGING S.P.A. (IT) | 2005-04-07 | — | — | US | disclosed |
| EP-1404376-A2 | RADIOPHARMACEUTICAL FORMULATIONS | Bracco Imaging SPA (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2002032294-A2 | RADIOPHARMACEUTICAL FORMULATIONS | BRACCO RESEARCH USA (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187198-A1 | Methods of preparing substituted tetracyclines with transition metal-based chemistries | TET1, TET3, DDT | KMT2A 526/4885CA12 3530/4885CA1 2913/4885 |
| US-20110085975-A1 | HYPOXIA-SELECTIVE, WEAKLY BASIC 2-NITROIMIDAZOLE DELIVERY AGENTS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, NUCB2 | KMT2A 749/4885CA12 140/4885CA1 216/4885 |
| US-20080102026-A1 | Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof | HIF1AN, HIF1A, NUCB2 | KMT2A 749/4885CA12 140/4885CA1 216/4885 |
| US-20050074402-A1 | Radiopharmaceutical formulations | SDHB, GPX4, SDHA | KMT2A 4656/4885CA12 1762/4885CA1 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.